Outlook Therapeutics, Inc. OTLK
Set alert
0.47 USD -0.03 -5.15%
At close · Oct 30
0.47 +0.01 +1.28%
After hours · Oct 30, 7:49 PM ET
0.45 Day range 0.4929
0.198 52-week range 2.47
- YTD
- -70.37%
- 1 year
- -62.25%
- Open
- 0.49
- Prev close
- 0.4935
- Mkt cap
- 113.96M
- Vol
- 4.79M
- Avg vol
- 10.25M
- EPS
- -0.70
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.45
- High
- 0.4929
- Forward P/E
- -0.55
- Beta
- 0.63
- Short ratio
- 1.26
- Inst. own
- 35.63%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Dec 27, 2024
- 50-d avg
- 4.24
- 200-d avg
- 6.73
- 1y target
- 24.80
2Y chart
Events in this range
- Nov 29, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Nov 29, 2024Rating: BTIG · Buy → Buy
- Dec 2, 2024Downgrade: Chardan Capital · Buy → Neutral
- Dec 27, 2024Earnings: —; estimate -0.83; surprise —%
Signals (75)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 14, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 14, 2026 | 2 weeks ago |
| MACD: Buy Signal | Sep 1, 2026 | 2 months ago |
| SMA: Bearish | Aug 13, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 13, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 12, 2026 | 2 months ago |
| SMA: Bullish | Aug 4, 2026 | 2 months ago |
| SMA: Bearish | Aug 3, 2026 | 2 months ago |
| SMA: Bullish | Jul 29, 2026 | 3 months ago |
| SMA: Bearish | Jul 28, 2026 | 3 months ago |
| SMA: Bearish | Jul 27, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 1, 2026 | 4 months ago |
| SMA: Bullish | Jun 10, 2026 | 4 months ago |
| RSI: Overbought | Jun 10, 2026 | 4 months ago |
| RSI: Overbought | May 27, 2026 | 5 months ago |
| SMA: Bullish | May 20, 2026 | 5 months ago |
| MACD: Buy Signal | May 19, 2026 | 5 months ago |
| MACD: Sell Signal | May 6, 2026 | 5 months ago |
| SMA: Bearish | Apr 21, 2026 | 6 months ago |
| SMA: Bullish | Apr 20, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 7, 2026 | 6 months ago |
| RSI: Oversold | Apr 6, 2026 | 6 months ago |
| MACD: Sell Signal | Mar 24, 2026 | 7 months ago |
| RSI: Oversold | Mar 24, 2026 | 7 months ago |
| MACD: Buy Signal | Jan 26, 2026 | 9 months ago |
| RSI: Oversold | Jan 2, 2026 | 10 months ago |
| SMA: Bearish | Dec 31, 2025 | 10 months ago |
| SMA: Bearish | Dec 31, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 19, 2025 | 10 months ago |
| RSI: Overbought | Dec 16, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 15, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 12, 2025 | 10 months ago |
| SMA: Bullish | Nov 17, 2025 | 11 months ago |
| RSI: Overbought | Nov 17, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 13, 2025 | 11 months ago |
| SMA: Bullish | Oct 31, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 30, 2025 | 1 year ago |
| SMA: Bearish | Oct 27, 2025 | 1 year ago |
| SMA: Bullish | Oct 24, 2025 | 1 year ago |
| SMA: Bearish | Oct 21, 2025 | 1 year ago |
| SMA: Bullish | Oct 20, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 19, 2025 | 1 year ago |
| RSI: Oversold | Aug 29, 2025 | 1 year ago |
| SMA: Bearish | Aug 28, 2025 | 1 year ago |
| SMA: Bearish | Aug 28, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 28, 2025 | 1 year ago |
| RSI: Overbought | Aug 25, 2025 | 1 year ago |
| RSI: Overbought | Aug 18, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 14, 2025 | 1 year ago |
| SMA: Bullish | Aug 11, 2025 | 1 year ago |
| SMA: Bearish | Aug 6, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 24, 2025 | 1 year ago |
| RSI: Overbought | Jul 14, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 7, 2025 | 1 year ago |
| SMA: Bullish | Jul 2, 2025 | 1 year ago |
| SMA: Bearish | Jun 27, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 11, 2025 | 1 year ago |
| MACD: Buy Signal | May 30, 2025 | 1 year ago |
| MACD: Sell Signal | May 22, 2025 | 1 year ago |
| RSI: Overbought | May 13, 2025 | 1 year ago |
| MACD: Buy Signal | May 12, 2025 | 1 year ago |
| SMA: Bullish | May 8, 2025 | 1 year ago |
| MACD: Sell Signal | May 7, 2025 | 1 year ago |
| SMA: Bullish | Apr 21, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 10, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 28, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 5, 2025 | 1 year ago |
| RSI: Oversold | Feb 27, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 24, 2025 | 1 year ago |
| SMA: Bearish | Feb 18, 2025 | 1 year ago |
| SMA: Bullish | Feb 14, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 12, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 7, 2025 | 1 year ago |
| RSI: Oversold | Nov 27, 2024 | 1 year ago |
Key statistics
- Market cap
- 33.59M
- Enterprise value
- 34.76M
- Trailing P/E
- 0.00
- Forward P/E
- -0.55
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -5.89
- Beta
- 0.63
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -43.59M
- Total cash
- 32.02M
- Total debt
- 32.72M
- Return on equity
- 0.00%
- Shares outstanding
- 23.66M
- Short % of float
- 25.71%
- 50-day average
- 4.24
- 200-day average
- 6.73
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 24.80 +5198.0% upside
Now 0.4681
- Target (low)
- 9.00
- Target (mean)
- 24.80
- Target (high)
- 38.00
Ratings (0m) 6 5 buy · 1 hold · 0 sell
- Strong buy1
- Buy4
- Hold1
- Sell0
- Strong sell0
Next earnings
Dec 27, 2024
Expected Dec 27, 2024. Consensus EPS estimate -0.90.
Financials — quick view
OTLK Revenue — quarterly 8.70K
OTLK Net income — quarterly -20.32M
OTLK EPS — quarterly -0.15
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 27, 2024 | Sep 1, 2024 | -0.83 | — | — | — |
| Aug 14, 2024 | Jun 1, 2024 | -1.06 | -0.83 | +0.23 | +21.70% |
| May 15, 2024 | Mar 1, 2024 | -0.88 | -1.55 | -0.67 | -76.14% |
| Feb 14, 2024 | Dec 1, 2023 | -1.00 | -0.80 | +0.20 | +20.00% |
| Dec 22, 2023 | Sep 1, 2023 | -1.00 | -1.00 | 0.00 | 0.00% |
| Aug 14, 2023 | Jun 1, 2023 | -0.80 | -1.60 | -0.80 | -100.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 2, 2024 | Chardan Capital | down | Buy | Neutral |
| Nov 29, 2024 | BTIG | main | Buy | Buy |
| Nov 29, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 16, 2024 | Chardan Capital | main | Buy | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 17, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- outlooktherapeutics.com
News
- Outlook Therapeutics Files Application With Centers For Medicare & Medicaid Services Seeking Healthcare Common Procedure Coding System Level II J-Code For LYTENAVA To Treat Macular Degeneration
- Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10.5
- 5 Stocks In The Spotlight Last Week: Wall Street's Most Accurate Analysts Weigh In
- BTIG Reiterates Buy on Outlook Therapeutics, Maintains $4 Price Target
- 12 Health Care Stocks Moving In Friday's Intraday Session
- Transcript: Outlook Therapeutics Q3 2026 Earnings Conference Call
- Outlook Therapeutics Q3 Adj. EPS $(0.09), Inline, Sales $9.000K Miss $5.300M Estimate
- S&P 500 Hits New Record High Following PPI Data: Investor Sentiment Improves, Fear Index Remains In ‘Greed’ Zone
- Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
- 12 Health Care Stocks Moving In Thursday's Intraday Session
Your note
Sign in to keep a note on OTLK — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DAGNON TERRY | Chief Operating Officer | Sale | Apr 19, 2023 | 653,058 |
| EVANSON JEFF | Officer | Purchase | Mar 6, 2024 | 808,459 |
| HADDADIN YEZAN MUNTHER | Director | Purchase | Mar 27, 2024 | 5,048 |
| KENYON LAWRENCE A. | Chief Financial Officer | Purchase | Sep 25, 2024 | 5,946 |
| SUKHTIAN GHIATH M | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Mar 17, 2024 | 0 |
| SYNTONE VENTURES, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 14, 2024 | 1,705,440 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Tang Capital Management, LLC | 6.59% | 1,559,560 | 2.21M | Sep 29, 2024 |
| Great Point Partners LLC | 5.47% | 1,293,028 | 1.84M | Sep 29, 2024 |
| Blackrock Inc. | 4.42% | 1,044,988 | 1.48M | Sep 29, 2024 |
| Vanguard Group Inc | 3.62% | 855,876 | 1.22M | Sep 29, 2024 |
| Altium Capital Management, LP | 2.29% | 541,549 | 769.00K | Sep 29, 2024 |
| Rosalind Advisors, Inc. | 1.90% | 450,000 | 639.00K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.87% | 442,511 | 628.37K | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.56% | 369,414 | 524.57K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.19% | 281,280 | 399.42K | Sep 29, 2024 |
| iShares Russell 2000 Growth ETF | 0.44% | 103,672 | 147.21K | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.35% | 82,266 | 116.82K | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 0.34% | 79,464 | 112.84K | Aug 30, 2024 |